JP6501947B2 - 抗腫瘍化合物 - Google Patents

抗腫瘍化合物 Download PDF

Info

Publication number
JP6501947B2
JP6501947B2 JP2018086737A JP2018086737A JP6501947B2 JP 6501947 B2 JP6501947 B2 JP 6501947B2 JP 2018086737 A JP2018086737 A JP 2018086737A JP 2018086737 A JP2018086737 A JP 2018086737A JP 6501947 B2 JP6501947 B2 JP 6501947B2
Authority
JP
Japan
Prior art keywords
cancer
compound
formula
lung cancer
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018086737A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018188432A5 (enExample
JP2018188432A (ja
Inventor
マリア・デル・カルメン・ケヴァス・マルシャンテ
アンドレス・フランセスク・ソリョーソ
バレンティン・マルティネス・バラサ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharma Mrs sA
Original Assignee
Pharma Mrs sA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharma Mrs sA filed Critical Pharma Mrs sA
Publication of JP2018188432A publication Critical patent/JP2018188432A/ja
Publication of JP2018188432A5 publication Critical patent/JP2018188432A5/ja
Application granted granted Critical
Publication of JP6501947B2 publication Critical patent/JP6501947B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2018086737A 2017-04-27 2018-04-27 抗腫瘍化合物 Active JP6501947B2 (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP17382228 2017-04-27
EP17382228.9 2017-04-27
EP17382497 2017-07-26
EP17382497.0 2017-07-26

Publications (3)

Publication Number Publication Date
JP2018188432A JP2018188432A (ja) 2018-11-29
JP2018188432A5 JP2018188432A5 (enExample) 2019-01-17
JP6501947B2 true JP6501947B2 (ja) 2019-04-17

Family

ID=62063080

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2018086737A Active JP6501947B2 (ja) 2017-04-27 2018-04-27 抗腫瘍化合物
JP2018086736A Active JP6501946B2 (ja) 2017-04-27 2018-04-27 抗腫瘍化合物
JP2019558467A Active JP7186723B2 (ja) 2017-04-27 2018-04-27 抗腫瘍化合物
JP2022107785A Active JP7422812B2 (ja) 2017-04-27 2022-07-04 抗腫瘍化合物
JP2023008821A Active JP7490835B2 (ja) 2017-04-27 2023-01-24 抗腫瘍化合物

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2018086736A Active JP6501946B2 (ja) 2017-04-27 2018-04-27 抗腫瘍化合物
JP2019558467A Active JP7186723B2 (ja) 2017-04-27 2018-04-27 抗腫瘍化合物
JP2022107785A Active JP7422812B2 (ja) 2017-04-27 2022-07-04 抗腫瘍化合物
JP2023008821A Active JP7490835B2 (ja) 2017-04-27 2023-01-24 抗腫瘍化合物

Country Status (39)

Country Link
US (5) US11332480B2 (enExample)
EP (5) EP3395821B1 (enExample)
JP (5) JP6501947B2 (enExample)
KR (3) KR102510975B1 (enExample)
CN (4) CN117865987A (enExample)
AU (4) AU2018260314C1 (enExample)
BR (1) BR112019022282A2 (enExample)
CA (1) CA3061518A1 (enExample)
CL (1) CL2019003057A1 (enExample)
CO (1) CO2019011967A2 (enExample)
CY (3) CY1121884T1 (enExample)
DK (5) DK4047002T3 (enExample)
EC (1) ECSP19083967A (enExample)
ES (5) ES2740073T3 (enExample)
FI (3) FI4047002T3 (enExample)
HK (2) HK1255938B (enExample)
HR (5) HRP20230433T1 (enExample)
HU (5) HUE062157T2 (enExample)
IL (3) IL270153B2 (enExample)
JO (1) JOP20190254A1 (enExample)
LT (5) LT4047002T (enExample)
MA (2) MA44020B1 (enExample)
MD (5) MD4101855T2 (enExample)
ME (2) ME03466B (enExample)
MX (3) MX392829B (enExample)
MY (1) MY198004A (enExample)
PH (1) PH12019550224A1 (enExample)
PL (5) PL3395821T3 (enExample)
PT (2) PT3395820T (enExample)
RS (5) RS64686B1 (enExample)
SA (1) SA523440283B1 (enExample)
SG (2) SG10201913300YA (enExample)
SI (5) SI4047002T1 (enExample)
SM (5) SMT202300160T1 (enExample)
TN (2) TN2019000211A1 (enExample)
TW (3) TWI875118B (enExample)
UY (1) UY37706A (enExample)
WO (1) WO2018197663A1 (enExample)
ZA (1) ZA201907119B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020517709A (ja) * 2017-04-27 2020-06-18 ファルマ、マール、ソシエダード、アノニマＰｈａｒｍａ Ｍａｒ，Ｓ．Ａ． 抗腫瘍化合物

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI824043B (zh) * 2018-10-25 2023-12-01 西班牙商瑪製藥股份有限公司 藥物抗體共軛物
CN118924687A (zh) * 2019-11-21 2024-11-12 法马马有限公司 用鲁比卡丁制剂治疗小细胞肺癌的方法
CN115427081B (zh) * 2020-04-21 2025-12-09 法马马有限公司 药物抗体共轭物
TW202144369A (zh) * 2020-04-26 2021-12-01 大陸商江蘇恆瑞醫藥股份有限公司 海鞘素類衍生物及其製備方法與醫藥用途
WO2022243482A1 (en) 2021-05-19 2022-11-24 Pharma Mar, S.A. Dosage regimens for ecubectedin
WO2024186263A1 (en) * 2023-03-07 2024-09-12 Axcynsis Therapeutics Pte. Ltd. Antibody-drug conjugates comprising trabectedin and lurbinectedin derivatives
WO2025077996A1 (en) 2023-10-09 2025-04-17 Pharma Mar, S.A. Synthetic process for the manufacture of ecteinascidin compounds
EP4563149A1 (en) 2023-11-30 2025-06-04 Pharma Mar, S.A. Lurbinectedin, ecubectedin and a related compound for use in the treatment of skin cancers
WO2025168075A1 (zh) * 2024-02-08 2025-08-14 映恩生物科技(上海)有限公司 海鞘素类化合物及其应用
WO2025228595A1 (en) 2024-04-30 2025-11-06 Pharma Mar, S.A. Use of compound ia in the treatment of cancers including combination therapy with atezolizumab.
WO2025228594A1 (en) 2024-04-30 2025-11-06 Pharma Mar, S.A. Use of ecubectedin in the treatment of cancers including combination therapy with atezolizumab
WO2025228596A1 (en) 2024-04-30 2025-11-06 Pharma Mar, S.A. Combination of pm14 and a topoisomerase i inhibitor in the treatment of cancer
WO2025228597A1 (en) 2024-04-30 2025-11-06 Pharma Mar, S.A. Combination of compound ia and a topoisomerase i inhibitor in the treatment of cancer
WO2025233522A1 (en) 2024-05-10 2025-11-13 Pharma Mar, S.A. Synthetic process for an ecteinascidin

Family Cites Families (220)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3205220A (en) 1961-10-26 1965-09-07 Lilly Co Eli Leurosidine and leurocristine and their production
US4762949A (en) 1979-06-20 1988-08-09 University Of Illinois Foundation Acyl and carbamimidoyl alkanediamines
GB2058047B (en) 1979-07-11 1983-09-21 Asahi Chemical Ind Amides and amidines
FR2461995A1 (fr) 1979-07-20 1981-02-06 Lcc Cice Cie Europ Compo Elect Transducteur magneto-electrique pour systeme d'enregistrement magnetique, et systeme d'enregistrement comportant un tel transducteur
US4950649A (en) 1980-09-12 1990-08-21 University Of Illinois Didemnins and nordidemnins
US5137870A (en) 1980-09-12 1992-08-11 The Board Of Trustees Of The University Of Illinois Didemnins and nordidemnins
US4782135A (en) 1980-09-12 1988-11-01 Board Of Trustees, University Of Illinois Composition of matter and process
US4493796A (en) 1980-09-12 1985-01-15 Board Of Trustees, Univ. Of Ill. Didemnins A, B, C, and derivatives thereof, as antiviral agents
DE3161556D1 (en) 1980-09-12 1984-01-05 Univ Illinois Novel antibiotics, derivatives thereof, processes for their extraction, and compositions containing them
US4548814A (en) 1980-12-18 1985-10-22 The Board Of Trustees Of The University Of Illinois Composition of matter and process
JPS5922518A (ja) 1982-07-29 1984-02-04 余合住金産業株式会社 洋服タンス
IT1153974B (it) 1982-09-23 1987-01-21 Erba Farmitalia Composizioni farmacologiche a base di cisplatino e metodo per il loro ottenimento
US4855086A (en) 1982-10-15 1989-08-08 Burroughs Wellcome Co. Novel pesticides, preparation and use
US4537883A (en) 1982-11-12 1985-08-27 Mead Johnson & Company Lyophilized cyclophosphamide
JPS59225189A (ja) 1983-06-03 1984-12-18 Shionogi & Co Ltd キノナミン誘導体およびその製造法
US4631149A (en) 1983-07-25 1986-12-23 University Of Illinois Antiviral eudistomins from a marine tunicate
JPS6084288A (ja) 1983-10-13 1985-05-13 Shionogi & Co Ltd シアノキノナミンアセテ−ト類およびその製造法
US4567253A (en) 1984-02-03 1986-01-28 Tony Durst 2-Substituted derivatives of podophyllotoxin and etoposide
JPS61109717A (ja) 1984-11-02 1986-05-28 Teruhiko Beppu 抗腫瘍剤
ATE68186T1 (de) 1984-12-28 1991-10-15 Conpharm Ab Verwendung von podophyllotoxin und dessen derivaten.
US4644072A (en) 1985-04-12 1987-02-17 Bristol-Myers Company Intermediates for the production of epipodophyllotoxin and related compounds and processes for the preparation and use thereof
DE3684868D1 (de) 1985-09-20 1992-05-21 Cernitin Sa Verwendung von pflanzenpollenextrakten zur herstellung von das wachstum von tumorzellen hemmenden pharmazeutischen praeparaten und verfahren zu ihrer herstellung.
US4731377A (en) 1986-01-31 1988-03-15 Harbor Branch Oceanographic Institute, Inc. Antitumor cyclic peroxides
US5256663A (en) 1986-06-09 1993-10-26 The Board Of Trustees Of The University Of Illinois Compositions comprising ecteinascidins and a method of treating herpes simplex virus infections therewith
US5089273A (en) 1986-06-09 1992-02-18 Board Of Trustees Of The University Of Illinois Ecteinascidins 729, 743, 745, 759A, 759B and 770
AU589282B2 (en) 1986-06-09 1989-10-05 University Of Illinois Ecteinascidins 729, 743, 745, 759a, 759b and 770
US5149804A (en) 1990-11-30 1992-09-22 The Board Of Trustees Of The University Of Illinois Ecteinascidins 736 and 722
US4816450A (en) 1986-09-15 1989-03-28 Duke University Inhibition of protein kinase C by long-chain bases
US4737510A (en) 1986-09-30 1988-04-12 The Board Of Trustees Of The University Of Illinois Bioactive metabolites from the caribbean sponge agelas coniferin
US5093330A (en) 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
US4847246A (en) 1987-09-11 1989-07-11 Wilson George R Antiviral compositions derived from fireflies and their methods of use
FR2623504B1 (fr) 1987-11-25 1990-03-09 Adir Nouveaux derives n-(vinblastinoyl-23) d'acide amino-1 methylphosphonique, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent
US5559145A (en) 1988-06-01 1996-09-24 Oxaco S.A. 1,2,4-trioxane derivatives
EP0358418B1 (en) 1988-09-05 1992-12-16 Sankyo Company Limited Cyclic peptide, its preparation and its use in the treatment of cardiovascular disorders
WO1990005731A1 (en) 1988-11-24 1990-05-31 University Of Queensland Cytotoxic macromolecules
US5190876A (en) 1988-12-27 1993-03-02 Emory University Method of modifying cellular differentiation and function and compositions therefor
CA2007507C (en) 1989-02-03 1998-05-19 Yasuyuki Igarashi Sphingosine and n-methyl-sphingosine as inhibitor of cell growth
US5583160A (en) 1989-02-03 1996-12-10 The Biomembrane Institute Methylsphingosine used to treat apoptosis
US4948791A (en) 1989-04-10 1990-08-14 The Board Of Trustees Of The University Of Illinois Novel Cytotoxic cyclic depsipeptides from the tunicate trididemnum solidum
US4986988A (en) 1989-05-18 1991-01-22 Arizona Board Of Regents Isolation and structural elucidation of the cytostatic linear depsipeptides dolastatin 13 and dehydrodolastatin 13
US20030148933A1 (en) 1990-10-01 2003-08-07 Pharma Mar S.A. Derivatives of dehydrodidemnin B
GB8922026D0 (en) 1989-09-29 1989-11-15 Pharma Mar Sa Novel anti-viral and cytotoxic agent
US5053559A (en) 1989-12-29 1991-10-01 Oxaco S.A. Cleavage of 1,2,4-trioxanes
KR910014122A (ko) 1990-01-19 1991-08-31 디께다 가즈히꼬 에토포시드-2-디메틸아미노 화합물의 동결건조 제제
JPH0539283A (ja) 1991-01-31 1993-02-19 Suntory Ltd 新規物質Ｓ−５９９１７ａ及びその製造方法
US5721352A (en) 1991-02-19 1998-02-24 University Of Florida Research Foundation Entomopoxvirus expression system
DE4120327A1 (de) 1991-06-20 1992-12-24 Basf Ag Neue peptide, ihre herstellung und verwendung
US5336669A (en) 1991-12-10 1994-08-09 Erbamont, Inc. Cyclophosphamide monohydrate and lactose
JPH05247055A (ja) 1992-03-03 1993-09-24 Meiji Seika Kaisha Ltd スタウロスポリン誘導体及びそれを含有する抗腫瘍効果増強剤
GB9206244D0 (en) 1992-03-23 1992-05-06 Pharma Mar Sa Cytotoxic compound from a marine sponge
GB9212000D0 (en) 1992-06-05 1992-07-15 Univ Madrid Complutense New synthetic antitumoral compound
CA2140653A1 (en) 1992-08-12 1994-03-03 Irene Abraham Protein kinase inhibitors and related compounds combined with taxol
US5756734A (en) 1992-09-11 1998-05-26 Pharmamar, S.A. Crambescidins: new antiviral and cytotoxic compounds from the sponge crambe crambe
ES2059259B1 (es) 1992-09-22 1995-10-01 Pharma Mar S A Pharmar Procedimiento de obtencion de nuevos areno (e)indoles utiles como intermedios en la sintesis de productos con actividad antitumoral.
US5580871A (en) 1992-11-20 1996-12-03 The Dupont Merck Pharmaceutical Company 4-Heteroaryl- 1,4-dihydropyridine compounds with calcium agonist and alpha1 -antagonist activity
GB9302046D0 (en) 1993-02-03 1993-03-24 Pharma Mar Sa Antiumoral compound-v
GB9302044D0 (en) 1993-02-03 1993-03-24 Pharma Mar Sa Cytotoxic compounds i
US6274551B1 (en) 1994-02-03 2001-08-14 Pharmamar, S.A. Cytotoxic and antiviral compound
US5569757A (en) 1993-03-30 1996-10-29 Rinehart; Kenneth L. 9-deazaadenosine and its 5'-α-D-glycopyranoside isolated from the cyanobacterium anabaena affinis strain VS-1
GB9308111D0 (en) 1993-04-20 1993-06-02 Pharma Gen S A Active compound from a stonge
US5556777A (en) 1993-09-09 1996-09-17 Pharmamar, S.A. Immunosuppressive pharmaceutical compositions new biological activity from a marine agrobacterium sp.
US5478932A (en) 1993-12-02 1995-12-26 The Board Of Trustees Of The University Of Illinois Ecteinascidins
US5462726A (en) 1993-12-17 1995-10-31 Bristol-Myers Squibb Company Method of inhibiting side effects of solvents containing ricinoleic acid or castor oil or derivatives thereof employing a thromboxane A2 receptor antagonist and pharmaceutical compositions containing such solvents
US20040059112A1 (en) 1994-02-18 2004-03-25 Rinehart Kenneth L. Ecteinascidins
US5514708A (en) 1994-02-18 1996-05-07 Pharmamar, S.A. Cytotoxic metabolites from Myriapora truncata
US5681813A (en) 1994-04-06 1997-10-28 Pharma Mar, S.A. Thiodepsipeptide isolated from a marine actinomycete
ES2100124B1 (es) 1994-08-01 1998-04-01 Pharma Mar Sa Perfeccionamientos introducidos en la p.i. 9401697 por terpeno-quinonas con actividad antitumoral.
US5514705A (en) 1994-09-07 1996-05-07 Pharmamar, S.A. Epidioxymanadic acids A and B
US5523456A (en) 1994-09-29 1996-06-04 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
GB9422947D0 (en) 1994-11-14 1995-01-04 Univ Salamanca Immunosuppressive cyclolignan derivatives
GB9422946D0 (en) 1994-11-14 1995-01-04 Univ Salamanca Antineoplastic cyclolignan derivatives
GB9504662D0 (en) 1995-03-08 1995-04-26 Pharma Mar Sa Antitumour isocoumarins
US20010039041A1 (en) 1995-06-07 2001-11-08 Pharma Mar, S.A. Immunosuppressive sesbanimide compositions and methods of treatment using same
US5661175A (en) 1995-06-20 1997-08-26 Kashman; Yoel Hemiasterlin and geodiamolide TA
US5852033A (en) 1995-06-29 1998-12-22 Pharma Mar, S.A. Methods of treatment using lamellarin-class alkaloids
ES2102322B1 (es) 1995-07-13 1998-03-01 Pharma Mar Sa Procedimiento de preparacion de didemnina a.
US5681847A (en) 1995-12-05 1997-10-28 Harbor Branch Oceanographic Institution, Inc. Methods of using discodermolide compounds
EP0821068A3 (en) 1996-03-29 1999-06-02 Rohm And Haas Company Novel sphingolipids and a process thereto
GB9608010D0 (en) 1996-04-18 1996-06-19 Pharma Mar Sa Trunkamide A
US6156724A (en) 1996-06-07 2000-12-05 Rinehart; Kenneth L. Uses of didemnins as immunomodulating agents
US5721362A (en) 1996-09-18 1998-02-24 President And Fellows Of Harvard College Process for producing ecteinascidin compounds
DE69723728T2 (de) 1996-10-24 2004-06-03 The Board Of Trustees For The University Of Illinois, Urbana Totalsynthese des amino hip analogen von didemnin a
WO1998017275A1 (en) 1996-10-24 1998-04-30 The Board Of Trustees Of The University Of Illinois Semi-synthetic studies toward didemnin analogues
GB9622427D0 (en) 1996-10-28 1997-01-08 Pharma Mar Sa Antimalarial drugs
US6028077A (en) 1997-04-15 2000-02-22 Rinehart; Kenneth L. Crambescidin compounds
US6034058A (en) 1997-04-15 2000-03-07 Rinehart; Kenneth L. Semi-synthetic alanyl dilemnin analogs
US6107520A (en) 1997-04-15 2000-08-22 The Board Of Trustees Of The University Of Illinois Spisulosine compounds
US5985876A (en) 1997-04-15 1999-11-16 Univ Illinois Nucleophile substituted ecteinascidins and N-oxide ecteinascidins
USRE38793E1 (en) 1997-04-15 2005-09-06 Rinehart Kenneth L Spisulosine compounds
US6800661B1 (en) 1997-04-15 2004-10-05 Board Of Trustees Of The University Of Illinois Spisulosine compounds
AUPO656597A0 (en) 1997-05-02 1997-05-29 Australian National University, The Preparation of therapeutic compounds
EP0981352B8 (en) 1997-05-07 2009-06-17 Pharma Mar, S.A. Use of aplidine for the treatment of cardiovascular diseases
GB9723206D0 (en) 1997-11-03 1998-01-07 Inst Biomar Sa New cytotoxic pyridoacridine alkaloids
US6420357B1 (en) 1997-12-23 2002-07-16 Instituto Biomar, S.A. Cytotoxic alkaloid derivatives including Asmarine A and B isolated from a sponge
GB9727301D0 (en) 1997-12-23 1998-02-25 Inst Biomar Sa Asmarine A and B: New cytotoxic alkaloids
GB9801741D0 (en) 1998-01-27 1998-03-25 Inst Biomar Sa New cytotoxic tris (oxazole)-containing macrolides
GB9803448D0 (en) 1998-02-18 1998-04-15 Pharma Mar Sa Pharmaceutical formulation
BR9909488B1 (pt) 1998-04-06 2011-02-08 ecteinascidinas semi-sintéticas e composição farmacêutica.
US6656948B2 (en) 1998-04-29 2003-12-02 Universidad Complutense De Madrid Cytotoxic compounds: derivatives of the pyrido[2,3,4-kl]acridine ring system
WO1999056535A1 (en) 1998-05-05 1999-11-11 Pharma Mar, S.A. Culture of sessile marine animals
RU2225864C2 (ru) * 1998-05-11 2004-03-20 Фарма Мар, С.А. Метаболиты эктейнасцидина-743, фармацевтическая композиция на их основе и способы лечения
GB9810998D0 (en) 1998-05-21 1998-07-22 Univ Madrid Complutense Antitumour 1,5-diazaanthraquinones
US6124292A (en) 1998-09-30 2000-09-26 President And Fellows Of Harvard College Synthetic analogs of ecteinascidin-743
GB9821975D0 (en) 1998-10-08 1998-12-02 Pharma Mar Sa New cytotoxic alkaloids
US6245759B1 (en) 1999-03-11 2001-06-12 Merck & Co., Inc. Tyrosine kinase inhibitors
MY164077A (en) 1999-05-13 2017-11-30 Pharma Mar Sa Compositions and uses of et743 for treating cancer
GB9918178D0 (en) 2000-05-15 1999-10-06 Pharma Mar Sa Synthetic methods
AR035842A1 (es) 1999-05-14 2004-07-21 Pharma Mar Sa Metodo de hemisintesis para la formacion de compuestos intermediarios y derivados y de estructuras relacionadas con la ecteinascidina y de tetrahidroisoquinolinfenoles y compuestos intermediarios de aplicacion en dicho metodo
GB9915069D0 (en) 1999-06-28 1999-08-25 Inst Biomar Sa New indolocarbazole alkaloids from a marine actinomycete
US6635677B2 (en) 1999-08-13 2003-10-21 Case Western Reserve University Methoxyamine combinations in the treatment of cancer
NZ518847A (en) 1999-11-15 2004-02-27 Pharma Mar S Aplidine treatment of cancers
US6686470B2 (en) 2000-01-19 2004-02-03 The Trustees Of Columbia University In The City Of New York Compounds of the saframycin-ecteinascidin series, uses, and synthesis thereof
GB0002952D0 (en) 2000-02-09 2000-03-29 Pharma Mar Sa Process for producing kahalalide F compounds
JP2003523338A (ja) 2000-02-16 2003-08-05 ファルマ・マール・ソシエダード・アノニマ 抗腫瘍活性を有するオキシ−及びアミノ−置換テトラヒドロフリル誘導体
US20030187075A1 (en) 2000-03-20 2003-10-02 Junichi Tanaka Keith Sponge antitumor compounds
BR0109958A (pt) 2000-04-07 2003-05-27 Univ Pennsylvania Análogos de didemnina e tamandarina e métodos de preparação e uso deles
US6509315B1 (en) 2000-04-07 2003-01-21 The Trustees Of The University Of Pennsylvania Didemnin analogs and fragments and methods of making and using them
US7919493B2 (en) 2000-04-12 2011-04-05 Pharma Mar, S.A. Anititumoral ecteinascidin derivatives
PT1280809E (pt) 2000-04-12 2005-11-30 Pharma Mar Sa Derivados antitumorais de ecteinascidina
GB0010799D0 (en) 2000-05-04 2000-06-28 Inst Biomar Sa Stolonoxides
MXPA02011319A (es) 2000-05-15 2003-06-06 Pharma Mar Sa Analogos antitumorales de ecteinascidina 743.
US7420051B2 (en) 2000-05-15 2008-09-02 Pharma Mar, S.A. Synthetic process for the manufacture of an ecteinaschidin compound
GB0011927D0 (en) 2000-05-17 2000-07-05 Inst Biomar Sa New use of citreamicins
DE60131076T2 (de) 2000-06-06 2008-07-31 Pharma Mar, S.A., Tres Cantos Antitumorale verbindungen
GB0016020D0 (en) 2000-06-29 2000-08-23 Inst Biomar Sa New polyciclic xanthones and their use
UA76718C2 (uk) 2000-06-30 2006-09-15 Фарма Мар, С.А. Протипухлинні похідні аплідину
EP1299388B1 (en) 2000-07-11 2009-05-13 Pharma Mar, S.A. Variolin derivatives as anti-cancer agents
EP2275174B1 (en) 2000-07-13 2016-04-20 ReCor Medical, Inc. Thermal treatment apparatus with ultrasound energy application
GB0019117D0 (en) 2000-08-03 2000-09-27 Univ Barcelona Derivatives of variolin B
KR20030038812A (ko) 2000-10-12 2003-05-16 파르마 마르, 에스.에이. 암 치료 방법
MXPA03003230A (es) 2000-10-12 2004-12-03 Pharma Mar Sa Tratamiento de canceres.
WO2002036145A2 (en) 2000-10-31 2002-05-10 Pharma Mar, S.A. Kahalalide f formulation
NZ525730A (en) 2000-11-06 2004-12-24 Pharma Mar S Compositions for antitumour treatments containing Ecteinascidin 743
GB0030417D0 (en) 2000-12-13 2001-01-24 Pharma Mar Sa An anticancer lead compound isolated from a New Zealand ascidian
WO2002058688A1 (de) 2001-01-24 2002-08-01 Mestex Ag Verwendung von neurotoxischen substanzen für die herstellung eines mittels zur behandlung von gelenkschmerzen
IL156580A0 (en) 2001-01-25 2004-01-04 Bristol Myers Squibb Co A method for formulating an epothilone analog for parenteral use and pharmaceutical preparations including an epothilone analog
EP1360337A1 (en) 2001-02-09 2003-11-12 The Regents Of The University Of California Ecteinascidin family compounds: compositions and methods
GB0105745D0 (en) 2001-03-08 2001-04-25 Pharma Gen S A Immobilisation of ligands
GB0108234D0 (en) 2001-04-02 2001-05-23 Pharma Mar Sa Process for producing trunkamide A compounds
GB0116966D0 (en) 2001-07-11 2001-09-05 Pharma Mar Sa Anittumoral compounds
GB0117402D0 (en) 2001-07-17 2001-09-05 Pharma Mar Sa New antitumoral derivatives of et-743
GB0119243D0 (en) 2001-08-07 2001-10-03 Pharma Mar Sa Antitumoral analogs of ET-743
EP1435988A4 (en) 2001-10-19 2008-01-09 Pharmamar Sa IMPROVED USE OF ANTI-TUMORAL COMPOUND IN THE TREATMENT OF CANCER
WO2003033012A1 (en) 2001-10-19 2003-04-24 Pharma Mar, S.A. Kahalalide compounds for use in cancer therapy
US20050054555A1 (en) 2001-10-19 2005-03-10 Jose Jimeno Kahalalide compounds for use in cancer therapy
US20050004012A1 (en) 2001-10-19 2005-01-06 Ramon Mangues Use of aplidine for the treatment of pancreatic cancer
GB0202544D0 (en) 2002-02-04 2002-03-20 Pharma Mar Sa The synthesis of naturally occuring ecteinascidins and related compounds
US20040019027A1 (en) 2002-04-12 2004-01-29 Barry Forman Method of treating cerebrotendinous xanthomatosis
GB0217638D0 (en) 2002-07-30 2002-09-11 Pharma Mar Sa Total synthesis of myriaporones
ES2544527T3 (es) 2002-07-31 2015-09-01 Seattle Genetics, Inc. Conjugados de fármacos y su uso para tratar el cáncer, una enfermedad autoinmune o una enfermedad infecciosa
GB0218816D0 (en) 2002-08-13 2002-09-18 Pharma Mar Sa Antitumoral analogs of lamellarins
GB0218813D0 (en) 2002-08-13 2002-09-18 Pharma Mar Sa DNA sequences from an endosymbiont and their uses
US20040033940A1 (en) 2002-08-16 2004-02-19 Pharma Mar, S.A. Cyclic hepta-peptide derivative from colonial ascidians, lissoclinum SP
NZ539093A (en) 2002-10-18 2007-10-26 Pharma Mar Sau 4-methylhexanoic kahalaide F compound
GB0304367D0 (en) 2003-02-26 2003-04-02 Pharma Mar Sau Methods for treating psoriasis
GB0229793D0 (en) 2002-12-20 2003-01-29 Pharma Mar Sa The gene cluster involved in safracin biosynthesis and its uses for genetic engineering
GB0303940D0 (en) 2003-02-20 2003-03-26 Pharma Mar Sau Solid phase synthesis of antitumoral compounds
JP5356648B2 (ja) 2003-02-20 2013-12-04 シアトル ジェネティックス， インコーポレイテッド 抗ｃｄ７０抗体−医薬結合体、ならびに癌および免疫障害の処置のためのそれらの使用
US7507708B2 (en) 2003-02-26 2009-03-24 Pharma Mar, S.A.U. Antitumoral compounds
CN100409895C (zh) 2003-03-12 2008-08-13 法马马有限公司 用于治疗白血病和淋巴瘤的阿普立定组合
WO2004080477A1 (en) 2003-03-12 2004-09-23 Dana-Farber Cancer Institute, Inc. Aplidine for multiple myeloma treatment
CA2519234A1 (en) 2003-03-21 2004-10-07 Madeleine M. Joullie Tamandarin analogs and fragments thereof and methods of making and using
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
GB0312407D0 (en) 2003-05-29 2003-07-02 Pharma Mar Sau Treatment
KR20060031809A (ko) 2003-06-09 2006-04-13 더 리젠츠 오브 더 유니버시티 오브 미시간 암 치료 및 진단용 조성물 및 방법
GB0314726D0 (en) 2003-06-24 2003-07-30 Inst Biomar Sa New cytotoxic depsipeptides
AU2004263287B2 (en) 2003-07-25 2009-02-12 Novartis Ag Substituted lactams and their use as anti-cancer agents
GB0321066D0 (en) 2003-09-09 2003-10-08 Pharma Mar Sau New antitumoral compounds
DE602004018811D1 (de) 2003-10-09 2009-02-12 Abbott Lab Pyrrolidinylharnstoffderivate als angiogeneseinhibitoren
GB0324201D0 (en) 2003-10-15 2003-11-19 Pharma Mar Sau Improved antitumoral combinations
SI1689404T1 (sl) 2003-11-13 2009-02-28 Pharma Mar Sau Kombinacija et-743 s 5-fluorouracil pro zdravili za zdravljenje raka
AU2004291037A1 (en) * 2003-11-14 2005-06-02 Pharma Mar, S.A. Combination therapy comprising the use of ET-743 and paclitaxel for treating cancer
GB0326486D0 (en) 2003-11-14 2003-12-17 Pharma Mar Sau Combination treatment
DE102004011809A1 (de) 2004-03-11 2005-09-29 Robert Bosch Gmbh Magnetsensoranordnung
GB0408958D0 (en) 2004-04-22 2004-05-26 Pharma Mar Sa Convergent synthesis for kahalalide compounds
WO2005118584A2 (en) 2004-05-26 2005-12-15 Axys Pharmaceuticals, Inc. Saframycin analogs as therapeutic agents in the treatment of cancer
US7446196B2 (en) 2004-06-03 2008-11-04 Kosan Biosciences, Incorporated Leptomycin compounds
JP2008505862A (ja) 2004-07-09 2008-02-28 ファルマ、マール、ソシエダード、アノニマ 予後分子マーカー
CN101068596A (zh) 2004-09-29 2007-11-07 法马马私人股份有限公司 艾可特耐思地作抗炎药
UA87877C2 (en) 2004-10-26 2009-08-25 Фарма Мар С.А., Сосьедад Униперсональ Pegylated liposomal doxorubicin in combination with ecteinescidin 743
BRPI0517238B1 (pt) 2004-10-29 2021-11-09 Pharma Mar, S.A. Composições que compreendem ecteinascidina e um dissacarídeo, método para produzir um frasco que contém a referida composição e para preparar uma solução para infusão intravenosa e uso da referida solução
EP1817059A2 (en) 2004-12-01 2007-08-15 Genentech, Inc. Conjugates of 1,8-bis-naphthalimides with an antibody
WO2006066183A2 (en) 2004-12-16 2006-06-22 Axys Pharmaceuticals, Inc. Novel saframycin analogs as therapeutic agents
US20100216817A1 (en) 2005-05-03 2010-08-26 Pharma Mar Sa Antitumoral Tetrahydro-Pyrimidines
GB0515673D0 (en) 2005-08-01 2005-09-07 Pharma Mar Sa Antitumoral compounds
CN101278050A (zh) 2005-08-02 2008-10-01 马尔药品公司 参与噻可拉林生物合成的基因和噻可拉林的异源产生
GB0522082D0 (en) 2005-10-31 2005-12-07 Pharma Mar Sa Formulations
GB0523098D0 (en) 2005-11-14 2005-12-21 Pharma Mar Sa Antitumoral compounds
WO2007062413A2 (en) 2005-11-25 2007-05-31 University Of Medicine And Dentistry Of New Jersey Use of parp-1 inhibitors
ES2276629B1 (es) 2005-12-15 2009-04-01 Pharma Mar, S.A. Compuestos antitumorales.
ES2288107B1 (es) 2006-01-27 2008-11-01 Fundacion Imabis Instituto Mediterraneo Para El Avance De La Biotecnologia Y La Investigacion Sanita Derivados aciclicos saturados e insaturados de cadena larga de sulfamidas como activadores especificos de receptores ppar-alfa.
EP2029155B1 (en) 2006-02-28 2016-04-13 Pharma Mar S.A. Improved treatment of multiple myeloma
EP2023931A2 (en) 2006-05-12 2009-02-18 Pharma Mar S.A. Anticancer treatments with a combination of docetaxel and ecteinascidin
EP1864682A1 (en) 2006-06-09 2007-12-12 Sanofi-Aventis Leptomycin derivatives
PL2032551T3 (pl) 2006-06-16 2012-01-31 Pharma Mar Sa Przeciwnowotworowe związki dihydropiran-2-onu
US20100240595A1 (en) 2007-10-19 2010-09-23 Pharma Mar ,S.A. Improved Antitumoral Treatments
AU2008313634A1 (en) 2007-10-19 2009-04-23 Pharma Mar, S.A. Prognostic molecular markers for ET-743 treatment
NZ584695A (en) 2007-10-19 2011-06-30 Pharma Mar Sa Improved antitumoral treatments using PM02734 and an EGFR tyrosine kinase inhibitor (erlotinib)
WO2009077401A1 (en) 2007-12-14 2009-06-25 Pharma Mar, S.A. Antitumoral compounds
RU2489429C2 (ru) 2007-12-20 2013-08-10 Фарма Мар, С.А. Противоопухолевые соединения
US20100323021A1 (en) 2008-01-30 2010-12-23 Pharma Mar, S.A. Antitumoral treatments
MX2010009697A (es) 2008-03-07 2010-09-30 Pharm Mar S A Tratamientos anticancerigenos mejorados.
RU2010140890A (ru) 2008-03-07 2012-04-20 Фарма Мар, С.А. (Es) Улучшенные способы противоопухолевого лечения
AU2009248039B2 (en) 2008-05-16 2014-07-31 Pharma Mar, S.A. Multiple myeloma treatments
RU2010151602A (ru) 2008-05-16 2012-06-27 Фарма Мар, С.А. (Es) Комбинированная терапия с помощью рм00104 и другого противоопухолевого средства
SI2294072T1 (sl) 2008-05-23 2017-05-31 Wyeth Llc Triazinske spojine kot inhibitorji P13-kinaze in MTOR
MX2011000144A (es) 2008-07-03 2011-02-24 Pharma Mar Sa Compuestos antitumorales.
KR101667062B1 (ko) 2008-07-15 2016-10-17 제넨테크, 인크. 안트라시클린 유도체 접합체, 그의 제조 방법 및 항-종양 화합물로서의 그의 용도
RU2011105801A (ru) 2008-07-17 2012-08-27 Фарма Мар, С.А. (Es) Противораковые соединения
CA2745377A1 (en) 2008-12-19 2010-06-24 Pharma Mar, S.A. Anticancer compounds
WO2010149688A2 (en) 2009-06-24 2010-12-29 Pharma Mar, S.A. Antitumoral compounds
PL2563803T3 (pl) 2010-04-27 2016-08-31 Pharma Mar Sa Przeciwnowotworowe laktony steroidowe nienasycone w pozycji 7(8)
US9428524B2 (en) 2010-05-25 2016-08-30 Pharma Mar, S.A. Synthetic process for the manufacture of ecteinascidin compounds
EP2786756B1 (en) 2010-11-12 2020-03-11 Pharma Mar, S.A. Combination therapy with a topoisomerase inhibitor
DE102012211024B4 (de) 2012-06-27 2024-10-24 Robert Bosch Gmbh Verfahren zum Betreiben eines Fahrzeuges
JP5922518B2 (ja) 2012-07-20 2016-05-24 浜松ホトニクス株式会社 シンチレータパネル及び放射線検出器
GB201309807D0 (en) 2013-05-31 2013-07-17 Pharma Mar Sau Antibody drug conjugates
MX2019000536A (es) 2016-07-14 2019-04-01 Pfizer Nuevas pirimidinas carboxamidas como inhibidores de enzima vanina-1.
JOP20190254A1 (ar) * 2017-04-27 2019-10-27 Pharma Mar Sa مركبات مضادة للأورام
TWI824043B (zh) * 2018-10-25 2023-12-01 西班牙商瑪製藥股份有限公司 藥物抗體共軛物

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020517709A (ja) * 2017-04-27 2020-06-18 ファルマ、マール、ソシエダード、アノニマＰｈａｒｍａ Ｍａｒ，Ｓ．Ａ． 抗腫瘍化合物
JP7186723B2 (ja) 2017-04-27 2022-12-09 ファルマ、マール、ソシエダード、アノニマ 抗腫瘍化合物

Also Published As

Publication number Publication date
IL295044B2 (en) 2023-11-01
NZ797531A (en) 2025-06-27
EP4101855A1 (en) 2022-12-14
SG11201909841RA (en) 2019-11-28
JP2023052597A (ja) 2023-04-11
IL270153A (enExample) 2019-12-31
ES2740073T3 (es) 2020-02-05
JP7490835B2 (ja) 2024-05-27
JP6501946B2 (ja) 2019-04-17
JP7186723B2 (ja) 2022-12-09
TW202202509A (zh) 2022-01-16
HUE062157T2 (hu) 2023-10-28
US10538535B2 (en) 2020-01-21
HRP20231233T1 (hr) 2024-01-19
FI3615544T3 (fi) 2023-05-23
SMT202300169T1 (it) 2023-07-20
EP3395820A1 (en) 2018-10-31
MX392601B (es) 2025-03-24
MD3615544T2 (ro) 2023-08-31
HK1255941B (en) 2020-04-29
ES2944344T3 (es) 2023-06-20
SI3615544T1 (sl) 2023-07-31
PH12019550224A1 (en) 2020-10-12
SI3395821T1 (sl) 2019-09-30
CL2019003057A1 (es) 2020-02-21
PT3395821T (pt) 2019-08-27
SI4101855T1 (sl) 2024-03-29
LT3395820T (lt) 2019-08-12
DK3395821T3 (da) 2019-08-19
HUE062032T2 (hu) 2023-09-28
CN117865987A (zh) 2024-04-12
WO2018197663A1 (en) 2018-11-01
SI3395820T1 (sl) 2019-09-30
LT3615544T (lt) 2023-05-10
CY1121885T1 (el) 2020-10-14
NZ797532A (en) 2025-06-27
US20210246146A1 (en) 2021-08-12
CN110621678B (zh) 2024-09-20
MA44021B1 (fr) 2019-08-30
EP3395821B1 (en) 2019-05-15
CY1126061T1 (el) 2023-11-15
US20220242883A1 (en) 2022-08-04
RS64200B1 (sr) 2023-06-30
NZ758490A (en) 2025-06-27
EP4047002A1 (en) 2022-08-24
LT4101855T (lt) 2023-08-25
CA3061518A1 (en) 2018-11-01
PL3615544T3 (pl) 2023-07-17
PT3395820T (pt) 2019-08-07
SMT202300343T1 (it) 2023-11-13
TN2019000210A1 (en) 2021-01-07
MD4047002T2 (ro) 2023-08-31
FI4047002T3 (fi) 2023-05-22
EP3615544B1 (en) 2023-03-22
DK3395820T3 (da) 2019-08-12
KR102492283B1 (ko) 2023-01-27
IL289963A (en) 2022-03-01
CO2019011967A2 (es) 2020-02-18
HRP20191442T1 (hr) 2019-11-15
BR112019022282A2 (pt) 2020-05-19
MY198004A (en) 2023-07-25
EP4047002B1 (en) 2023-03-08
HUE045641T2 (hu) 2020-01-28
EP3395821A1 (en) 2018-10-31
CN114751920A (zh) 2022-07-15
MX2021016054A (es) 2022-06-01
ME03467B (me) 2020-01-20
US20180312529A1 (en) 2018-11-01
HK1255938B (en) 2020-04-29
LT3395821T (lt) 2019-08-12
KR20210126791A (ko) 2021-10-20
RS64686B1 (sr) 2023-11-30
TWI807411B (zh) 2023-07-01
TW202344509A (zh) 2023-11-16
CN114736219A (zh) 2022-07-12
IL289963B1 (en) 2023-06-01
EP3615544A1 (en) 2020-03-04
IL289963B2 (en) 2023-10-01
KR20220109495A (ko) 2022-08-04
EP3395820B1 (en) 2019-05-15
KR20200012846A (ko) 2020-02-05
HRP20230433T1 (hr) 2023-07-07
US11332480B2 (en) 2022-05-17
AU2022200249C1 (en) 2022-06-23
US20210070775A1 (en) 2021-03-11
MA44020B1 (fr) 2019-08-30
MD3395821T2 (ro) 2019-10-31
US12384800B2 (en) 2025-08-12
TN2019000211A1 (en) 2021-01-07
RS64174B1 (sr) 2023-05-31
PL3395821T3 (pl) 2019-10-31
UY37706A (es) 2018-11-30
DK3615544T3 (da) 2023-05-30
ES2741901T3 (es) 2020-02-12
ZA201907119B (en) 2021-07-28
DK4101855T3 (da) 2023-11-06
EP3615544B9 (en) 2024-01-03
ME03466B (me) 2020-01-20
AU2022201657A1 (en) 2022-03-31
HUE046109T2 (hu) 2020-02-28
HUE063736T2 (hu) 2024-01-28
SMT202300160T1 (it) 2023-07-20
AU2018260314B2 (en) 2021-12-09
KR102510975B1 (ko) 2023-03-16
AU2022200249B1 (en) 2022-02-10
IL295044B1 (en) 2023-07-01
KR102491180B1 (ko) 2023-01-20
SG10201913300YA (en) 2020-03-30
MA44020A (fr) 2018-10-31
RS59174B1 (sr) 2019-10-31
JP2018188432A (ja) 2018-11-29
DK4047002T3 (da) 2023-05-01
JOP20190254A1 (ar) 2019-10-27
MX2019012812A (es) 2020-01-14
CN110621678A (zh) 2019-12-27
TWI742273B (zh) 2021-10-11
FI4101855T3 (fi) 2023-09-22
TWI875118B (zh) 2025-03-01
JP2020517709A (ja) 2020-06-18
EP4101855B1 (en) 2023-08-02
IL270153B1 (en) 2023-06-01
LT4047002T (lt) 2023-05-10
PL4047002T3 (pl) 2023-07-24
RS59173B1 (sr) 2019-10-31
MX2021016058A (es) 2022-02-03
MX392829B (es) 2025-03-24
CN114736219B (zh) 2024-06-07
SA523440283B1 (ar) 2025-04-26
ES2960063T3 (es) 2024-02-29
ES2944579T3 (es) 2023-06-22
TW201906850A (zh) 2019-02-16
PL3395820T3 (pl) 2019-11-29
PL4101855T3 (pl) 2023-12-27
HRP20191443T1 (hr) 2019-11-15
ECSP19083967A (es) 2019-12-27
CY1121884T1 (el) 2020-10-14
JP7422812B2 (ja) 2024-01-26
JP2018188431A (ja) 2018-11-29
SMT201900447T1 (it) 2019-09-09
AU2022200250C1 (en) 2022-06-23
AU2018260314A1 (en) 2019-10-31
MD3395820T2 (ro) 2019-10-31
EP4101855B9 (en) 2024-01-03
HRP20230455T1 (hr) 2023-07-21
IL295044A (en) 2022-09-01
SI4047002T1 (sl) 2023-07-31
US20240166666A1 (en) 2024-05-23
JP2022130682A (ja) 2022-09-06
SMT201900448T1 (it) 2019-09-09
IL270153B2 (en) 2023-10-01
US11713325B2 (en) 2023-08-01
AU2022200250B1 (en) 2022-02-10
MD4101855T2 (ro) 2023-12-31
US11339180B2 (en) 2022-05-24
MA44021A (fr) 2019-05-15
AU2018260314C1 (en) 2022-04-21
CN114751920B (zh) 2024-06-07

Similar Documents

Publication Publication Date Title
JP6501947B2 (ja) 抗腫瘍化合物
HK1255941A1 (en) Antitumoral compounds
HK1255938A1 (en) Antitumoral compounds
ES2899372T3 (es) Combinación de tratamiento del cáncer de próstata, composición farmacéutica y método de tratamiento
US20050187148A1 (en) Antitumor agent
KR20130056249A (ko) 인지질 약물 유사체
US7951780B2 (en) Antitumor agent
AU2002237884B2 (en) Anticancer treatment using triptolide prodrugs
KR20190077476A (ko) 상글리페린 거대고리 유사체의 항암 화합물로서의 용도
KR20240004657A (ko) 종양 질환의 치료에서의 의약의 용도
JP4162994B2 (ja) 諸疾患状態の処置のための薬物に使用する化合物とその製造方法
WO2022235889A1 (en) Hsp90-binding conjugates and formulations thereof
CN101291675B (zh) 抗癌组合药物
WO2017142269A1 (ko) 신규한 인돌 유도체 및 이를 포함하는 항암 조성물
JP6803589B2 (ja) 抗腫瘍剤
RU2322236C2 (ru) Лекарственное средство для лечения доброкачественных и злокачественных опухолевых заболеваний, содержащее производное дисоразола
EP4534543A1 (en) Camptothecin prodrug and pharmaceutical composition thereof
KR20080066039A (ko) 신규 수용성 프로드러그를 함유하는 췌장암, 난소암 또는 간암의 예방 또는 치료제
CN106146612B (zh) 一类乙二醛酶i不可逆抑制剂及其制备方法和用途
WO2024247648A1 (ja) 腫瘍の治療剤及び複合体
US20070286906A1 (en) Dihydrobenzoquinone compounds
EA048329B1 (ru) Противоопухолевые соединения
EA048007B1 (ru) Противоопухолевые соединения

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181109

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20181109

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20181109

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20181121

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20181217

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190129

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190218

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20190319

R150 Certificate of patent or registration of utility model

Ref document number: 6501947

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250